In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes

American Journal of Obstetrics and Gynecology

Volumn 201, Issue 6, 2009, Pages 553-559

  Witter, Frank R ^a   Zimmerman, Andrew W ^a,b   Reichmann, James P ^c   Connors, Susan L ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c American Home Patient   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

asthma; autism spectrum disorder; beta 2 adrenergic agonist; preterm labor; ritodrine; terbutaline

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BUDESONIDE; CORTICOSTEROID; FENOTEROL; FORMOTEROL; ISOXSUPRINE; PLACEBO; RITODRINE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE;

ABSENCE OF SIDE EFFECTS; ACADEMIC ACHIEVEMENT; ASTHMA; AUTISM; BEHAVIOR DISORDER; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE; BRADYCARDIA; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CORTICOSTEROID THERAPY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; FETUS DISTRESS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GESTATION PERIOD; GLUCOSE TOLERANCE; HEART DISEASE; HEART MUSCLE NECROSIS; HEART RATE; HUMAN; HYPERTENSION; LANGUAGE DISABILITY; LOW DRUG DOSE; LUNG DISEASE; LUNG EDEMA; MAINTENANCE THERAPY; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROPHYSIOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL DEVELOPMENT; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SENSITIZATION; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TACHYPHYLAXIS; TERATOGENESIS; TOCOLYSIS; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT;

ABNORMALITIES, DRUG-INDUCED; ADRENERGIC AGONISTS; ASTHMA; BLOOD PRESSURE; BRONCHODILATOR AGENTS; FEMALE; FETAL DISTRESS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MENTAL DISORDERS; MOVEMENT DISORDERS; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTORS, ADRENERGIC, BETA-2; TOCOLYTIC AGENTS;

EID: 70649088022     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.07.010     Document Type: Review

References (87)

1. Cikos S., Veselá J., Il'ková G., Rehák P., Czikková S., and Koppel J. Expression of beta adrenergic receptors in mouse oocytes and preimplantation embryos. Mol Reprod Dev 71 (2005) 145-153
2. Slotkin T.A., Lau C., and Seidler F.J. Beta-adrenergic receptor overexpression in the fetal rat: distribution, receptor subtypes, and coupling to adenylate cyclase activity via G-proteins. Toxicol Appl Pharmacol 129 (1994) 223-234
3. Crespo P., Cachero T.G., Xu N., and Gutkind J.S. Dual effect of beta-adrenergic receptors on mitogen-activated protein kinase: evidence for a beta gamma-dependent activation and a G alpha s-cAMP-mediated inhibition. J Biol Chem 270 (1995) 25259-25265
4. Schmitt J.M., and Stork P.J. Beta 2 adrenergic receptor activates extracellular signal-related kinases (ERKs) via the small G protein rap1 and the serine/threonine kinase B-Raf. J Biol Chem 275 (2000) 25342-25350
5. Duncan C.P., Seidler F.J., Lappi S.E., and Slotkin T.A. Dual control of DNA synthesis by α- and β-adrenergic mechanisms in normoxic and hypoxic neonatal rat brain. Dev Brain Res 55 (1990) 29-33
6. Kwon J.H., Eves E.M., Farrell S., et al. Beta-adrenergic receptor activation promotes process outgrowth in an embryonic rat basal forebrain cell line and in primary neurons. Eur J Neurosci 8 (1996) 2042-2055
7. Gharami K., and Das S. Thyroid hormone-induced morphological differentiation and maturation of astrocytes are mediated through the beta-adrenergic receptor. J Neurochem 75 (2000) 1962-1969
8. Slotkin T.A., Auman J.T., and Seidler F.J. Ontogenesis of β-adrenoceptor signaling: implications for perinatal physiology and for fetal effects of tocolytic drugs. J Pharmacol Exp Ther 306 (2003) 1-7
9. Connors S.L. Prenatal beta 2 adrenergic receptor signaling and autism: dysmaturation and retained fetal function. In: Zimmerman A.W. (Ed). Autism: current theories and evidence (2008), Humana Press, Totowa, NJ 147-182
10. Bergman B., Bokstrom H., Borga O., Enk L., Hedner T., and Wangberg B. Transfer of terbutaline across the human placenta in late pregnancy. Eur J Respir Dis Suppl 134 (1984) 81-86
11. Hsu C.H., Robinson C.P., and Basmadjian G.P. Tissue distribution of 3H-terbutaline in rabbits. Life Sci 54 (1994) 1465-1469
12. Slotkin T.A., Tate C.A., Cousins M.M., and Seidler F.J. Beta-adrenoceptor signaling in the developing brain: sensitization or desensitization in response to terbutaline. Brain Res Dev Brain Res 131 (2001) 113-125
13. Meyer A., Seidler F.J., Aldridge J.E., and Slotkin T.A. Developmental exposure to terbutaline alters cell signaling in mature rat brain regions and augments the effects of subsequent neonatal exposure to the organophosphorus insecticide chlorpyrifos. Toxicol Appl Pharmacol 203 (2005) 154-166
14. Rhodes M.C., Seidler F.J., Abdel-Rahman A., et al. Terbutaline is a neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. J Pharmacol Exp Ther 308 (2004) 529-537
15. Zerrate M.C., Pletnikov M., Connors S.L., et al. Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism. J Pharmacol Exp Ther 322 (2007) 16-22
16. Vargas D.L., Nascimbene C., Krishnan C., Zimmerman A.W., and Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57 (2005) 67-81
17. Lam F., Elliott J., Jones J.S., et al. Clinical issues surrounding the use of terbutaline sulfate for preterm labor. Obstet Gynecol Surv 53 (1998) S85-S95
18. Goldenberg R.L. The management of preterm labor. Obstet Gynecol 100 (2002) 1020-1037
19. Tegner K., Nilsson H.T., Persson C.G., and Ryrfeldt A. Elimination pathways of terbutaline. Eur J Respir Dis Suppl 134 (1984) 93-100
20. Rice D., and Barone S. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 108 suppl 3 (2000) 511-513
21. Clancy B., Kersh B., Hyde J., Darlington R.B., Anand K.J.S., and Finlay B.L. Web-based method for translating neurodevelopment from laboratory species to humans. Neuroinformatics 5 (2007) 79-94
22. Feldman D.S., Elton T.S., Sun B., Martin M.M., and Ziolo M.T. Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure. Nat Clin Pract Cardiovasc Med 5 (2008) 208-218
23. El-Armouche A., and Eschenhagen T. Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev (2008 Dec 27) Epub ahead of print
24. Del Colle S., Morello F., Rabbia F., et al. Antihypertensive drugs and the sympathetic nervous system. J Cardiovasc Pharmacol 50 (2007) 487-496
25. Ming X., Julu P.O.O., Brimacombe M., Connor S., and Daniels M.L. Reduced cardiac parasympathetic activity in children with autism. Brain Dev 27 (2005) 509-516
26. Garofolo M.C., Seidler F.J., Auman J.T., and Slotkin T.A. Beta-adrenergic modulation of muscarinic cholinergic receptor expression and function in developing heart. Am J Phys Reg Integ Compar Physiol 282 (2002) R1356-R1363
27. Stern M.T., Parker S., Coplan J., and Feldman H. Expressive language delay in a toddler. Pediatrics 107 (2001) 905-909
28. Connors S.L., Crowell D.E., Eberhart C.G., et al. Beta 2-adrenergic receptor activation and genetic polymorphisms in autism: data from dizygotic twins. J Child Neurol 20 (2005) 876-884
29. Thrasher J.D., Kilburn K.Y., and Immers I.B. Autism, terbutaline and neurological impairment: Ramazzi Days 2007: 25th Anniversary Jubilee, Capri Italy. CR Online Journal. www.collegiumramazzini.org Accessed Dec. 15, 2008
30. Croen L.A., Grether J.K., Yoshida C.K., Odouli R., and Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med 159 (2005) 151-157
31. Pitzer M., Schmidt M.H., Esser G., and Laucht M. Child development after maternal tocolysis with beta-sympathomimetic drugs. Child Psychiatry Hum Dev 31 (2001) 165-182
32. Hadders-Algra M., Touwen B.C., and Huisjes H.J. Long-term follow-up of children prenatally exposed to ritodrine. BJOG 93 (1986) 156-161
33. Alvarez M., Pita S., Costas E., et al. Long term effects of ritodrine on blood pressure and heart rate of adolescents exposed during the prenatal stage. Eur J Obstet Gynecol Reprod Biol 59 (1995) 137-141
34. Brazy J.E., Eckerman C.O., and Gross S.J. Follow-up of infants of less than 1500 gm birth weight with antenatal isoxsuprine exposure. J Pediatr 102 (1983) 611-613
35. Polowczyk D., Tejani N., Lauersen N., and Siddiq F. Evaluation of seven- to nine-year-old children exposed to ritodrine in utero. Obstet Gynecol 64 (1984) 485-488
36. Freysz H., Willard D., Lehr A., Messer J., and Boog G. A long term evaluation of infants who received a beta-mimetic drug while in utero. J Perinat Med 5 (1977) 94-99
37. Svenningsen N.W. Follow-up studies on preterm infants after maternal beta-receptor agonist treatment. Acta Obstet Gynecol Scand Suppl 108 (1982) 67-70
38. Cockcroft J.R., Gazis A.G., Cross D.J., et al. Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 36 (2000) 371-375
39. Dishy V., Sofowora G.G., Xie H.G., et al. The effect of common polymorphisms of the beta 2 -adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 345 (2001) 1030-1035
40. Green S.A., Rathz D.A., Schuster A.J., and Liggett S.B. The Ile 164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol 421 (2001) 141-147
41. Lee D.K., Currie G.P., Hall I.P., Lima J.J., and Lipworth B.J. The arginine-16 beta 2-adrenoceptor polymorphism predisposes to broncho protective sub sensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 57 (2004) 68-75
42. Pinelli M., Giacchetti M., Acquaviva F., et al. Beta 2 -adrenergic receptor and UCP3 variants modulate the relationship between age and type 2 diabetes mellitus. BMC Med Genet 7 (2006) 85
43. Liggett S.B., Wagoner L.E., Craft L.L., et al. The Ile 164 beta 2 adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 102 (1998) 1534-1539
44. Wolk R., Snyder E.M., Somers V.K., Turner S.T., Olson L.J., and Johnson B.D. Arginine 16 glycine beta 2-adrenoceptor polymorphism and cardiovascular structure and function in patients with heart failure. J Am Soc Echocardiogr 20 (2007) 290-297
45. Jazdzewski K., Bednarczuk T., Stepnowska M., et al. Beta-2 adrenergic receptor gene polymorphism confers susceptibility to Graves disease. Int J Mol Med 19 (2007) 181-186
46. Xu B.Y., Huang D., Pirskanen R., and Lefvert A.K. Beta 2 -adrenergic receptor gene polymorphisms in myasthenia gravis (MG). Clin Exp Immunol 119 (2000) 156-160
47. Xu B.Y., Arlehag L., Rantapää-Dahlquist S.B., and Lefvert A.K. Beta 2-adrenergic receptor gene single-nucleotide polymorphisms are associated with rheumatoid arthritis in northern Sweden. Scand J Rheumatol 33 (2004) 395-398
48. Kawaguchi H., Masuo K., Katsuya T., et al. Beta 2 - and beta3-adrenoceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals. Hypertens Res 29 (2006) 951-959
49. Busjahn A., Freier K., Faulhaber H.D., et al. Beta 2 adrenergic receptor gene variations and coping styles in twins. Biol Psychol 61 (2002) 97-109
50. Cheslack-Postava K., Fallin M.D., Avramopoulos D., et al. Beta 2-adrenergic receptor gene variants and risk for autism in the AGRE cohort. Mol Psychiatry 12 (2007) 283-291
51. National Institutes of Health. National asthma education report of the working group on asthma and pregnancy: management of asthma during pregnancy, recommendation for pharmacologic treatment update 2004 (2005), National Institutes of Health, Bethesda, MD
52. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M., and SMART Study Group. The salmeterol multicenter asthma research trial. Chest 129 (2006) 15-26
53. Salpeter S.R., Buckley N.S., Ormiston T.M., and Salpeter E.E. Meta-analysis: effect of long-acting beta agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144 (2006) 904-912
54. Cates C.J., and Cates M.J. Regular treatment with salmeterol for chronic asthma: serious adverse events (review). Cochrane Database System Rev 3 (2008) CD006363
55. Pollard S.J., Spector S.L., Yancey S.W., Cox F.M., and Emmett A. Salmeterol versus theophylline in the treatment of asthma. Ann Allergy Asthma Immunol 78 (1997) 457-464
56. Briggs C.G., Freeman R.K., and Yaffe S.J. Salmeterol. In: Briggs G.G., Freeman R.K., and Yaffe S.J. (Eds). Drugs in pregnancy and lactation. 8th ed. (2008), Lippincott, Williams, and Wilkins, Philadelphia 1645-1647
57. Leveno K.J., Little B.B., and Cunningham F.G. The national impact of ritodrine hydrochloride for inhibition of preterm labor. Obstet Gynecol 76 (1990) 12-15
58. Beall M.H., Edgar B.W., Paul R.H., and Smith-Wallace T. A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. Am J Obstet Gynecol 153 (1985) 854-859
59. Caritis S.N., Toig G., Heddinger L.A., and Ashmead G. A double-blind study comparing ritodrine and terbutaline in the treatment of preterm labor. Am J Obstet Gynecol 150 (1984) 7-14
60. Besinger R.E., and Niebyl J.R. The safety and efficacy of tocolytic agents for the treatment of preterm labor. Obstet Gynecol Surv 45 (1990) 415-440
61. Spellacy W.N., Cruz A.C., Birk S.A., and Buhi W.C. Treatment of premature labor with ritodrine: a randomized controlled study. Obstet Gynecol 5 (1979) 220-223
62. Larsen J.F., Eldon K., Lange A.P., et al. Ritodrine in the treatment of preterm labor: Second Danish Multicenter Study. Obstet Gynecol 67 (1986) 607-613
63. Wesselius-de Casparis A., Thiery M., Yo le Sian A., et al. Results of double-blinded, multicentre study with ritodrine in preterm labour. BMJ 3 (1971) 144-147
64. Berkman N.D., Thorp Jr. J.M., Lohr K.N., et al. Tocolytic treatment for the management of preterm labor: a review of the evidence. Am J Obstet Gynecol 188 (2003) 1648-1659
65. The Canadian Preterm Labor Investigation Group. Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N Engl J Med 327 (1992) 308-312
66. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 43: management of preterm labor. Obstet Gynecol 101 (2003) 1039-1047
67. Wenstrom K.D., Weiner C.P., Merrill D., and Niebyl J. A placebo-controlled randomized trial of the terbutaline pump for prevention of preterm delivery. Am J Perinatol 14 (1997) 87-91
68. Guinn D.A., Goepfert A.R., Owen J., Wenstrom K.D., and Hauth J.C. Terbutaline pump maintenance therapy for prevention of preterm delivery: a double-blind trial. Am J Obstet Gynecol 179 (1998) 874-878
69. Nanda K., Cook L.A., Gallo M.F., and Grimes D.A. Terbutaline pump maintenance therapy after threatened preterm labor for preventing preterm birth. Cochrane Database Syst Rev 4 (2002) CD003933
70. Agency for Healthcare Research and Quality (AHRQ). Systemic review of the literature regarding the management of preterm labor: summary, evidence report/technical assessment, no. 18 (2000), Agency for Healthcare Research and Quality, Rockville, MD
71. Perry Jr. K.G., Morrison J.C., Rust O.A., Sullivan C.A., Martin R.W., and Naef III R.W. Incidence of adverse cardiopulmonary effects with low-dose continuous terbutaline infusion. Am J Obstet Gynecol 173 (1995) 1273-1277
72. Elliott J.P., Istwan N.B., Rhea D., and Stanziano G. The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy. Am J Obstet Gynecol 191 (2004) 1277-1282
73. Quinn P.G., Sherman B.W., Tavill A.S., and Gibes A.L. Terbutaline hepatitis pregnancy report of two cases and literature review. Am J Gastroenterol 89 (1994) 781-784
74. Hudgens D.R., and Conrad S.E. Sudden death associated with terbutaline sulfate administration. Am J Obstet Gynecol 169 (1993) 120-121
75. Regenstein A.C., Belluomini J., and Katz M. Terbutaline tocolysis and glucose intolerance. Obstet Gynecol 81 (1993) 739-741
76. Lindenbaum C., Ludmin J., Teplick F.B., Cohen A.W., and Samuels P. Maternal glucose intolerance and the subcutaneous terbutaline pump. Am J Obstet Gynecol 166 (1993) 925-928
77. Fletcher S.I., Fyfe D.A., Case C.L., Wiles H.B., Upshur J.K., and Newman R.B. Myocardial necrosis in a newborn after long-term maternal subcutaneous terbutaline infusion for suppression of preterm labor. Am J Obstet Gynecol 165 (1991) 1401-1404
78. Fox N.S., Gelber S.E., Kalish R.B., and Chase S.T. Contemporary practice patterns and beliefs regarding tocolysis among US maternal-fetal medicine specialists. Obstet Gynecol 112 (2008) 42-47
79. Brown S.M., and Tejani N.A. Terbutaline sulfate in the prevention of recurrence of premature labor. Obstet Gynecol 57 (1981) 22-25
80. Lewis R., Mercer B.M., Salana M., Walsh M.A., and Sibas B.M. Oral terbutaline after parenteral tocolysis: a randomized, double-bind, placebo-controlled trial. Am J Obstet Gynecol 175 (1996) 834-837
81. Dodd J.M., Crowther C.A., Dare M.R., and Middleton P. Oral betaminetics for maintenance therapy after threatened preterm labor. Cochrane Database of Syst Rev I (2006) CD003927
82. Humphrey M., Chang A., Gilbert M., and Wood C. The effect of intravenous ritodrine on acid-base status of the fetus during the second stage of labor. BJOG 82 (1975) 234-245
83. Tejani N.A., Verma U.L., Chatterjec S., and Mittelmann S. Terbutaline the management of acute intrapartum fetal acidosis. J Reprod Med 28 (1983) 857-861
84. Ingermarsson I., Arulkumaran S., and Ratnam S.S. Single injection of terbutaline in term labor: I, effect on fetal pH in cases with prolonged bradycardia. Am J Obstet Gynecol 153 (1985) 859-865
85. Ingermarsson I., Arulkumaran S., and Ratnam S.S. Single injection of terbutaline in term labor: II, effect on uterine activity. Am J Obstet Gynecol 153 (1985) 865-869
86. Patriarco M.S., Viechnicki B.M., Hutchinson T.A., Klasko S.K., and Yeh S.Y. A study on intrauterine fetal resuscitation with terbutaline. Am J Obstet Gynecol 157 (1987) 384-387
87. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 70: intrapartum fetal heart rate monitoring. Obstet Gynecol 106 (2005) 1453-1461